- Home
- BIRD vs LSTA Comparison
BIRD vs LSTA Comparison
Compare BIRD & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIRD | LSTA |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 28.9M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | BIRD | LSTA |
|---|---|---|
| Price | $3.99 | $3.14 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $8.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.1M | 43.3K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.22 | ★ 20.42 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $152,466,000.00 | $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $35.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $2.15 | $1.81 |
| 52 Week High | $24.31 | $5.07 |
Technical Indicators
Market Signals| Indicator | BIRD | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 38.47 |
| Support Level | $3.85 | $2.75 |
| Resistance Level | $4.55 | $3.41 |
| Average True Range (ATR) | 0.47 | 0.13 |
| MACD | -0.34 | 0.05 |
| Stochastic Oscillator | 4.61 | 36.59 |
Price Performance
Historical ComparisonAbout BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.